Background: Respiratory muscle strength is used diagnostically in clinical practice and as an outcome measure in clinical trials in various chronic lung diseases. There is limited data on its repeatability in people with non-CF bronchiectasis. The aim of the present study was to assess the repeatability of maximal inspiratory (P I max) and expiratory pressures (P E max) in a group of patients with stable, moderate-to-severe non-CF bronchiectasis. Methods: Twenty participants with stable moderate-to-severe non-CF bronchiectasis were recruited. Respiratory muscle strength measurements (three maximal inspiratory and expiratory pressures) were made on 2 separate days. A standard protocol was used, including practice tests, before obtaining three technically acceptable and reproducible readings with a difference of 10% or less between values. Clinical trial registration number: ClinicalTrials.gov: NCT00487149. Results: The mean (SD) age of the non-CF bronchiectasis group was 63 (9) years. Maximal inspiratory pressures were repeatable with mean (SD) for highest P I max, Test 1 and Test 2, 75.90 (20) and 79.40 (19) cmH 2 O, and limits of agreement (mean difference + 2SD) -3.50 + 20 cmH 2 O, (p ¼ 0.14). Maximal expiratory pressures differed significantly with mean (SD) for highest P E max, Test 1 and Test 2, 102.25 (27) and 112.30 (32) cmH 2 O, and limits of agreement (mean difference + 2SD) -10.10 + 35 cmH 2 O, (p ¼ 0.02). The intraclass correlation coefficient (95% CI) for highest P I max and P E max was 0.93 (95% CI 0.82 to 0.97) and 0.90 (95% CI 0.76 to 0.96), respectively. Conclusion: Maximal inspiratory pressure measurements were repeatable during a period of clinical stability in moderate-to-severe non-CF bronchiectasis, suggesting this may be a useful outcome measure in non-CF bronchiectasis. Once a baseline has been established, a second visit is not required. P E max was not a repeatable measure and further study is necessary to ascertain how much practice testing is required to obtain an accurate value.
Introduction
The respiratory muscles play an important role in the development of symptoms and functional limitation associated with chronic respiratory disease. In the presence of inspiratory muscle weakness, a disparity between muscle load and capacity may arise, producing dyspnoea, reducing exercise capacity and promoting the development of hypoventilation and respiratory failure. [1] [2] [3] Reductions in expiratory muscle strength can impact on the efficiency of cough, thereby affecting removal of secretions from the airways. 3, 4 Previous work has suggested significant reductions in inspiratory muscle strength can occur during exacerbations of cystic fibrosis (CF). 5 The active intervention of airway clearance techniques may also cause respiratory muscle fatigue and airways closure and in some patients this may result in decrements in inspiratory and expiratory respiratory muscle performance. [6] [7] [8] When respiratory muscle weakness contributes to a respiratory problem in the spontaneously breathing non-CF bronchiectasis patient, recent guidelines recommend the introduction of specific interventions such as inspiratory muscle training or non-invasive ventilation. 8 Consequently, assessment of respiratory muscle strength may be clinically useful to monitor changes in disease over time, to identify those at risk of hypoventilation and to determine the impact of interventions.
Maximal inspiratory (P I max) and expiratory (P E max) pressures measured at the mouth are simple and well-tolerated manoeuvres that provide information about global respiratory muscle output. The equipment required to perform these measurements is portable and non-invasive, and testing can be performed readily at the bedside. Although 'normal' reference values have been established, these vary according to influencing factors such as age, height, gender, race, lung volumes, effort, malnutrition and respiratory disease. 9 Therefore, it is essential to use comparable reference values that closely reflect the demographics of the population being investigated in any research study or clinical situation. 2, 9 While the repeatability of P I max and P E max has been established in the 'healthy' population, 9, 10 there is limited data available for patients with non-CF bronchiectasis. Establishing repeatability of any outcome measure in a specific population is crucial to ensure that small changes in the measurement are discriminatory and interpretable. 11 This work was undertaken to establish the clinimetric property of reliability of respiratory muscle strength in a moderate-to-severe non-CF bronchiectasis population before including it as an outcome measure in a clinical study.
Therefore, the aim of this study was to investigate the repeatability of P I max and P E max in participants with stable non-CF bronchiectasis disease. A subsidiary aim was to identify how P I max and P E max in participants with non-CF bronchiectasis compared to normal reference values.
Methods Subjects
Twenty participants with non-CF bronchiectasis and stable, moderate-to-severe disease were recruited from the outpatient bronchiectasis clinic at Belfast City Hospital.
The inclusion criteria were over 40 years of age, non-smoker, able to perform lung function tests and available for repeat testing 10-14 days later; diagnosis of bronchiectasis by CT scan and where a differential diagnosis of CF was suspected, this was excluded by sweat chloride measurement and genetic testing; moderate-to-severe disease (FEV 1 < 60% predicted); stable, that is no administration of oral or intravenous antibiotics in the 3 weeks preceding the study, no change in timing, dosage or type of medication such as bronchodilators, oxygen, long-term prophylactic antibiotics or steroids in the preceding month; less that 10% variability in FEV 1 % predicted between the two testing sessions. 12 The FEV 1 % predicted value was reported as the European Coal Community Scale (ECCS). 13 Participants were excluded if they had any co-morbidity that could influence muscle strength. Recruitment took place between October 2005 and July 2008.
Ethical approval was obtained from ORECNI (REC reference 02/75) and informed written consent was obtained from all participants. This study was registered with ClinicalTrials.gov: NCT00487149.
Study design and methods
All measurements were obtained by one of three assessors. Pre-training ensured that all assessors followed standardized methodology. Initial measurements were made and then repeated again within a 10 to 14-day period. Measurements were made at the same time of day and there was no change in medication between days. Spirometry was conducted according to the ERS guidelines. 13 Respiratory muscle strength measurements were conducted according to the ATS standards. 9 A standard protocol was used including standardized, verbal instructions, demonstration of the procedure by the assessor and practice tests before obtaining three technically acceptable and reproducible readings, that is differences of 10% or less between values. Testing was performed with the patients seated and wearing nose clips. A rigid plastic-flanged mouthpiece was used to prevent air leaks from around the mouth, and during expiratory efforts, the patient used one hand to hold their cheeks. In a clinical setting, three manoeuvres that vary by less than 20% are acceptable for inspiratory and expiratory pressure measures. 9, [14] [15] [16] Maximum inspiratory mouth pressure (P I max) was measured from residual volume (RV) after maximal expiration. Maximum expiratory mouth pressure (P E max) was measured from total lung capacity (TLC) after a maximal inspiration. There was a 1min rest between each manoeuvre.
Respiratory muscle strength measurements were conducted using a handheld mouth pressure meter, a one-way inspiratory or expiratory valve, a singleuse, low-resistance bacterial filter, which does not affect the readings obtained from a respiratory muscle pressure machine, nose clips and a standard flanged mouthpiece (Micro Medical Ltd, UK). The pressure gauge calibration is factory-set and should remain stable indefinitely, with a small air leak (greater than 1mm in diameter) to reduce use of the buccal muscles. 17 Average pressures in cmH 2 O sustained over 2 sec were computed by the device and a microprocessor displayed a digital result which was recorded.
Statistical analysis
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS version 11.5). For each subject, the highest and mean of three consecutive P I max and P E max values were calculated. Preliminary analysis was performed to ensure no violation of the assumptions of normality, linearity and homoscedasticity. Values of p < 0.05 were considered significant. Paired t tests were used to assess changes in P I max and P E max values between the 2 test days. Bland and Altman plots were used to assess the limits of agreement between repeated P I max and P E max measures (defined as mean difference + 2SD). 18 Intraclass correlation coefficients (ICC) of reliability were determined for highest P I max and highest P E max to investigate whether the level of agreement between the two test sessions was sufficiently high. Pearson product-moment correlation coefficient was used to assess the relationship between spirometric measures of lung function and muscle strength.
Results
Of the 67 participants who fulfilled all inclusion criteria, 35 declined to participate. Reasons given were no intervention associated with the study therefore it was not of benefit to them as individuals; could not commit to the two time points due to work or family commitments; did not like undertaking tests that involved 'blowing out hard.' Twenty participants were available ( Figure 1 ) who met the criteria for clinical stability with no change in symptoms or medication and with less than 10% variability in FEV 1 between the two testing sessions, that is FEV 1 % predicted for Test 1 of 43 (10) and for Test 2 of 43 (11). The 9 male and 11 female participants had an age range of mean (SD) 63 (9) years. The underlying aetiology was due to childhood respiratory infections (n ¼ 10); idiopathic (n ¼ 3); connective tissue disease (n ¼ 3); immunodeficiency (n ¼ 2); autoimmune disease (n ¼ 1); TB (n ¼ 1).
No adverse effects or complications were observed during measurements.
There was no significant difference in P I max measurements between the two testing sessions (highest: p ¼ 0.14; mean: p ¼ 0.16, respectively) but P E max was significantly greater on Test 2 than Test 1 (highest: p ¼ 0.02; mean: p ¼ 0.04; Table 1 ). The mean differences and limits of agreement for P I max (mean + 2SD) were -3.50 + 20 cmH 2 O for highest P I max (Figure 2a ), and -4.00 + 25 cmH 2 O for mean P I max. The mean differences and limits of agreement for P E max (mean + 2SD) were -10.05 + 35 cmH 2 highest P E max (Figure 2b) , and -8.80 + 36 cmH 2 O for mean P E max. The ICC (95% CI) for the bronchiectasis population for highest P I max was 0.93 (95% CI 0.82 to 0.97) and highest P E max 0.90 (95% CI 0.76 to 0.96). FEV 1 % predicted did not differ between the two testing sessions (p ¼ 1.0; Table 1 
Discussion
This study aimed to assess the repeatability of P I max and P E max in participants with stable, moderate-tosevere non-CF bronchiectasis disease. The results suggest that for individuals with non-CF bronchiectasis, measurement of either highest or mean P I max is highly repeatable, showing little change between sessions during a period of clinical stability. In contrast, measurement of either highest or mean P E max showed significant variability between the two testing sessions. The results also suggest that participants with moderate-to-severe non-CF bronchiectasis demonstrated reduced inspiratory muscle strength compared to normal reference values ( Table 2) . No relationship between maximum inspiratory or expiratory pressures and FEV 1 % predicted was found in patients with non-CF bronchiectasis. The reported learning effect when measuring inspiratory muscle pressures in a COPD population 19 was not apparent in this study. A formal sample size calculation is not possible for reliability studies; however, the confidence intervals for the intraclass correlation coefficients in this study are narrow indicating that the sample size is adequate. Similar numbers were used in an intervention study, powered at 80% with a 0.05 significance level, which used respiratory muscle strength as an outcome measure in a non-CF bronchiectasis population. 20 Compromise of the respiratory muscles may occur in patients with lung disease secondary to factors such as dynamic hyperinflation, expiratory flow limitation, malnutrition, hypoxia and increased work of breathing. 3, 16, 21 For this reason, interest in measuring and monitoring respiratory muscle strength as an outcome measure has arisen. 3, 6, 7, 20 However, for such a measure to be useful, it must be shown to achieve good repeatability. 11 The current data demonstrates that in participants with non-CF bronchiectasis, P I max measurements show good repeatability over two testing sessions. This finding supports previous work that identified no change in inspiratory or expiratory muscle strength in a stable control group over an 8-week period. 20 Therefore, alterations in this measure associated with either a change in the patient's clinical condition or as a result of therapeutic intervention could provide useful and meaningful information. One study investigating the impact of exercise training in non-CF bronchiectasis compared the differences between an 8-week pulmonary rehabilitation versus pulmonary rehabilitation and inspiratory muscle training programme. 20 They demonstrated a small but significant improvement of 12 cmH 2 O (95%CI 1.1 to 22.9; p ¼ 0.05), in inspiratory muscle strength in the pulmonary rehabilitation group versus control and 21.4 cmH 2 O (95%CI 9.3 to 33.4; p ¼ 0.01) in the pulmonary rehabilitation and inspiratory muscle training group versus control. There was no difference in the magnitude of the increase in inspiratory muscle strength between the two groups (p ¼ 0.220). Since this data will be used to influence clinical management of a non-CF bronchiectasis population, it further justifies the importance of ensuring inspiratory muscle strength is a reliable outcome measure in non-CF bronchiectasis. 20 P E max was a less-repeatable measurement and produced a clinically unacceptable difference in participants with non-CF bronchiectasis. This was not anticipated since P E max replicates a respiratory manoeuvre that is familiar to people, that is cough, and studies in a healthy population have demonstrated that it is a repeatable measure. 9, 14, 22 Although the guidelines were followed, with practice occurring prior to testing, P E max was not a repeatable measure in this study. Further investigation is necessary to ascertain how much practice testing is required to obtain an accurate P E max value.
Normative P I max values vary considerably due to gender, age, equipment and methodological differences. 3 However a P I max of > 80 cmH 2 O (male) or >70 cmH 2 O (female) generally excludes clinically important inspiratory muscle weakness. 1, 23 Normative values for a group in the age range of the current study have been identified with Black et al. simplifying the technique used by Cook et al. 14, 22 (Table 2 ). In the current study, the mean highest P I max was less than 80 cmH 2 O on both occasions, which is in keeping with 'normative' values previously measured in a non-CF bronchiectasis population (Table 3 ). 20 The relationship between respiratory muscle strength and measures of dyspnoea or health-related quality of life outcome measures would need to be investigated before suggesting clinically significant respiratory muscle weakness may be present in this group of participants. 1 There maybe poor muscle co-ordination since the diaphragm is required to work from its maximal resting length to achieve the P I max manouvre; however one would have expected this to be overcome with practice. 24 In patients with non-CF bronchiectasis, changes in respiratory muscle pressures may be an earlier or more sensitive measurement to identify alterations in the clinical state of the patient in response to disease progression or the impact of a therapeutic intervention. 3 Respiratory muscle strength is an important additional outcome measurement providing more information for the clinician. Hospital sites could establish normative values for their specific patient populations if there is no existing data base to satisfy their specific clinical requirements. If this is not feasible then reference values from American Thoracic Society/European Respiratory Society guidelines should be carefully selected and chosen to best suit the population being tested ( Table 2 ). 9 Information from this current study has shown the reliability of maximum inspiratory muscle pressures, in stable non-CF bronchiectasis, providing evidence that these measurements can accurately reflect real changes in respiratory muscle strength.
Limitations of study
Tests of P I max and P E max are volitional so respiratory muscle strength may be underestimated and variable and reproducibility does not ensure that the effort made has been maximal. [24] [25] [26] In retrospect, it would have been helpful to measure dyspnoea as this is a symptom of respiratory muscle weakness. 3 Since this study has a small number of clinically stable patients, these results should not be generalized to those patients who have mild disease or those who are not clinically stable. Age can influence muscle strength and the age of the majority of patients in this study was over 50 years. These results also need to be confirmed in a younger non-CF bronchiectasis population.
Conclusion
In conclusion, respiratory muscle strength is a noninvasive measurement that is quick, simple and safe to perform.
This study provides new and important clinical information that inspiratory respiratory muscle strength measurements are reliable in a stable moderate-to-severe non-CF bronchiectasis population and could be used as one of the range of lung function outcome measures in the assessment of disease severity and treatment intervention over time. Future research should consider what constitutes a meaningful clinically important difference. 
